サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790306

乾癬性関節炎治療市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、投与経路別、地域別、セグメント別予測、2025年～2030年

Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 110 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
乾癬性関節炎治療市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、投与経路別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年07月29日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乾癬性関節炎治療市場サマリー

乾癬性関節炎治療の世界市場規模は2024年に113億5,000万米ドルと推計され、2025年から2030年にかけてCAGR 9.8%で成長し、2030年には199億1,000万米ドルに達すると予測されます。新製品の上市、有望なパイプライン、消費者意識の大幅な上昇、疾病負担の増加などが市場成長を促進する要因として期待されています。

乾癬性関節炎は乾癬に伴う慢性変性疾患です。適切かつタイムリーな治療が行われない場合、この疾患は不可逆的な関節障害を引き起こす可能性があります。正確な原因因子は未だ不明であるが、調査により症例の40％近くが遺伝的要因に起因することが示唆されています。

乾癬性関節炎は、関節リウマチや痛風と誤診されることがあります。しかし、民間および公的機関が組織する複数のキャンペーンに助けられ、消費者の意識が高まれば、誤診や誤った治療の割合は減少すると思われます。加えて、治療費の高騰と一部の薬剤の副作用が市場の成長を抑制すると予想されます。

生物学的製剤の標的作用とバイオシミラーの出現によって、関節症性乾癬の治療には大きなパラダイムシフトが起きています。しかし、安全性と有効性が改善された費用対効果の高い医薬品に対する消費者の需要は、市場力学にプラスの影響を与えると思われます。

新興市場におけるヘルスケアインフラの改善と保険適用の拡大も極めて重要です。アジア太平洋とラテンアメリカの国々では、医療制度が急速に改善され、高コストの生物学的製剤へのアクセスが拡大しています。これらの市場が成熟するにつれ、多国籍・国内医薬品メーカー双方にとって、これまで十分なサービスを受けていなかった人々を取り込む新たな機会がもたらされることになります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 乾癬性関節炎治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 乾癬性関節炎治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 乾癬性関節炎治療市場：薬剤クラスの推定・動向分析

  • 薬物クラスセグメントダッシュボード
  • 乾癬性関節炎治療市場：薬剤クラスの変動分析
  • 世界の乾癬性関節炎治療市場規模と動向分析（薬剤クラス別、2018～2030年）
  • NSAIDs
  • DMARD
  • 生物学的製剤
  • その他

第5章 乾癬性関節炎治療市場：タイプ推定・動向分析

  • タイプセグメントダッシュボード
  • 乾癬性関節炎治療市場：タイプ変動分析
  • 乾癬性関節炎治療の世界市場規模と動向分析（タイプ別、2018～2030年）
  • 処方箋
  • 市販薬

第6章 乾癬性関節炎治療市場：投与経路の推定・動向分析

  • 投与経路セグメントダッシュボード
  • 乾癬性関節炎治療市場：投与経路の変動分析
  • 世界の乾癬性関節炎治療市場規模と動向分析（投与経路別、2018～2030年）
  • 外用
  • 経口
  • 注射剤

第7章 乾癬性関節炎治療市場：地域推定・動向分析

  • 地域市場ダッシュボード
  • 地域別市場シェア分析、2024年および2030年
  • 地域別連続バイオプロセス市場：主なポイント
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • Key company heat map analysis, 2024
  • 企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Eli Lilly and Company
    • Pfizer, Inc.
    • UCB SA
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
  • Table 3 Global psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 4 Global psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 5 Global psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 6 North America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 7 North America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 8 North America psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 9 North America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 10 U.S. psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 11 U.S. psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 12 U.S. psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 13 Canada psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 14 Canada psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 15 Canada psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 16 Mexico psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 17 Mexico psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 18 Mexico surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 19 Europe psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 20 Europe psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 21 Europe psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 22 Europe psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 23 Germany psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 24 Germany psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 25 Germany psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 26 UK psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 27 UK psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 28 UK psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 29 France psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 30 France psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 31 France psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 32 Italy psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 33 Italy psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 34 Italy psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 35 Spain psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 36 Spain psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 37 Spain psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 38 Asia Pacific psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 39 Asia Pacific psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 40 Asia Pacific psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 41 Asia Pacific psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 42 China psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 43 China psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 44 China psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 45 Japan psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 46 Japan psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 47 Japan psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 48 India psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 49 India psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 50 India psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 51 South Korea psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 52 South Korea psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 53 South Korea psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 54 Australia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 55 Australia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 56 Australia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 57 Latin America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 58 Latin America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 59 Latin America surgical ablation market, by type (USD Million) 2018 - 2030
  • Table 60 Latin America laparoscopic ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 61 Latin America percutaneous ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 62 Latin America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 63 Brazil psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 64 Brazil psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 65 Brazil surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 66 Argentina psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 67 Argentina psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 68 Argentina surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 69 MEA psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
  • Table 70 MEA psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 71 MEA psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 72 MEA psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 73 South Africa psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 74 South Africa psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 75 South Africa psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 76 Saudi Arabia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 77 Saudi Arabia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 78 Saudi Arabia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 79 UAE psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 80 UAE psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 81 UAE psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Psoriatic arthritis treatment market: market outlook
  • Fig. 10 Psoriatic arthritis treatment competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Psoriatic arthritis treatment market driver impact
  • Fig. 16 Psoriatic arthritis treatment market restraint impact
  • Fig. 17 Psoriatic arthritis treatment market strategic initiatives analysis
  • Fig. 18 Psoriatic arthritis treatment market: Drug Class movement analysis
  • Fig. 19 Psoriatic arthritis treatment market: Drug Class outlook and key takeaways
  • Fig. 20 NSAIDs market estimates and forecast, 2018 - 2030
  • Fig. 21 DMARDs market estimates and forecast, 2018 - 2030
  • Fig. 22 Biologics market estimates and forecast, 2018 - 2030
  • Fig. 23 Others market estimates and forecast, 2018 - 2030
  • Fig. 24 Psoriatic arthritis treatment Market: Type movement Analysis
  • Fig. 25 Psoriatic arthritis treatment market: Type outlook and key takeaways
  • Fig. 26 Prescriptions market estimates and forecasts, 2018 - 2030
  • Fig. 27 OTC market estimates and forecasts,2018 - 2030
  • Fig. 28 Psoriatic arthritis treatment market: Route of Administration movement analysis
  • Fig. 29 Psoriatic arthritis treatment market: Route of Administration outlook and key takeaways
  • Fig. 30 Topical market estimates and forecasts, 2018 - 2030
  • Fig. 31 Oral market estimates and forecasts,2018 - 2030
  • Fig. 32 Injectable market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global psoriatic arthritis treatment market: Regional movement analysis
  • Fig. 34 Global psoriatic arthritis treatment market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 39 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 42 France market estimates and forecasts, 2018 - 2030
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 46 China market estimates and forecasts, 2018 - 2030
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 48 India market estimates and forecasts, 2018 - 2030
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-2-68038-990-6

Psoriatic Arthritis Treatment Market Summary

The global psoriatic arthritis market size was estimated at USD 11.35 billion in 2024 and is projected toprojected to reach USD 19.91 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The new product launches, promising pipeline, a significant rise in consumer awareness, and increasing disease burden are some factors expected to fuel market growth.

Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. In the absence of proper and timely treatment, the disease may lead to irreversible joint damage. Although the exact causative factors remain unknown, research suggests that nearly 40% of cases are attributable to genetic factors.

Psoriatic arthritis may be misdiagnosed as rheumatoid arthritis or gout. However, heightened consumer awareness, aided by multiple campaigns organized by private and public organizations, is likely to reduce the rates of misdiagnosis or incorrect treatment. In addition, the high cost of treatment and the adverse effects of some drugs are expected to restrain market growth.

There is a significant paradigm shift in the treatment of psoriatic arthritis, driven by the targeted action of biologics and the emergence of biosimilars. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.

Healthcare infrastructure improvements and increased insurance coverage in emerging markets are also pivotal. Countries in Asia-Pacific and Latin America are witnessing rapid health system upgrades, enabling wider access to high-cost biologic therapies. As these markets mature, they present new opportunities for both multinational and domestic drug makers to tap into previously underserved populations.

Global Psoriatic Arthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psoriatic arthritis market report based on drug class, type, route of administration, and region:

  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • NSAIDs
  • DMARD
  • Biologics
  • Others
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Prescriptions
  • OTC
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Topical
  • Oral
  • Injectable
  • Regional Outlook (Revenue, USD Million, 2018 - 2026)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class outlook
    • 2.2.2. Type outlook
    • 2.2.3. Route of Administration
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Psoriatic Arthritis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Psoriatic Arthritis Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Psoriatic Arthritis Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Psoriatic Arthritis Treatment Market: Drug Class Movement Analysis
  • 4.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. DMARDs
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Psoriatic Arthritis Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Psoriatic Arthritis Treatment Market: Type Movement Analysis
  • 5.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Prescriptions
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. OTC
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Psoriatic Arthritis Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Segment Dashboard
  • 6.2. Psoriatic Arthritis Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Topical
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Psoriatic Arthritis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. AbbVie Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Amgen Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson Services, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bristol-Myers Squibb Company
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Eli Lilly and Company
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Pfizer, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. UCB S.A.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives